FDA Approves Voceryq for Recurrent Respiratory Papillomatosis
The FDA granted accelerated approval to Voceryq, the first plasmid DNA-based immunotherapy approved in the US for adult patients with recurrent respiratory papillomatosis (RRP).
Tag: RRP respiratory papillomavirus
FDA Approves Voceryq for Recurrent Respiratory Papillomatosis
The FDA granted accelerated approval to Voceryq, the first plasmid DNA-based immunotherapy approved in the US for adult patients with recurrent respiratory papillomatosis (RRP).
Read More
New Standard of Care Recommended for Recurrent Respiratory Papillomatosis
Papzimeos (zopapogene imadenovec) is recommended as the new first-line treatment for adults with recurrent respiratory papillomatosis (RRP), which affects an estimated 27,000 US adults.
Read More
Human Respiratory Papillomavirus
Although many new treatments have been introduced, respiratory papillomatosis remains incurable.
Read More